Becton Dickinson & Co Surges to 225th in Trading Volume Despite Stock Decline

On March 25, 2025, Becton Dickinson & Co. (BDX) saw a significant increase in trading volume, with a turnover of $383 million, marking a 37.6% rise from the previous day. This surge placed BDX at the 225th position in terms of trading volume for the day. However, the stock price of BDX experienced a decline of 0.48%, marking the third consecutive day of decrease, with a total drop of 1.63% over the past three days.

Becton Dickinson & Co. has made notable progress in its clinical trial for the bioabsorbable GalaFLEX LITE scaffold. This advancement aims to enhance outcomes in breast implant revision surgeries and improve patient satisfaction. The successful completion of key milestones in this trial has the potential to drive the stock price higher, as investors anticipate the positive impact on the company's future performance.